

Marketing Communication


About Albemarle Asset Management

Founded in London in 2003. Companies house incorporation filing, 25 July 2003. The company provides individual and collective management services for private and institutional investors, financial and capital management consultancy, and managed investment solutions. Our expertise enables a diverse offering of investment instruments and strategies.


Performance: past returns doesn't predict future returns

	YTD	1M	6M	1YR	Inception
Fund	-0.40%	1.02%	-1.21%	-0.34%	-9.75%
	Best Mth	Worst Mth	CAGR	Volt.	Sharpe R.
Fund	-23.35%	9.89%	-1.57%	#VALUE!	requesting Da

Chart Performance *



Returns *



Different Share Classes

Class	NAV	YTD	1M	6M	1YR	Since Inception	Inception Date	ISIN	Management Fee
A	Daily	-0.83%	0.95%	-1.58%	-1.08%	-12.07%	05/02/2020	IE00B3BM9X16	1.5% p.a.

Albemarle Asset Management Limited, 21 Upper Brook Street, London W1K 7PY

Tel: +44 (0) 2072907730 - www.albemarleasset.com - albemarlefunds@albemarleasset.com

Fund Objective

Albemarle Longevity Fund is a sub-fund of Albemarle Funds Plc, an open-ended investment company with variable capital incorporated in Ireland. The fund objective is to achieve long term capital appreciation by investing in the Italian equity market. Please refer to page 2 for key risks. The fund is actively managed.

Fund Information


Company	Albemarle Funds Plc
Investment Manager	Albemarle Asset Management Ltd
Bloomberg	ATGASII ID
ISIN	IE00B50NJG20
Inception	05/02/2020
Currency	EUR
Fund Manager	Albemarle Asset Management Ltd
Management Fees	0.75% p.a. (Class I)
Benchmark	N/A
Performance Fees	15% of the amount by which the net asset value exceeds the high water mark
NAV	Daily
Cut-Off	T-1 before 1pm Irish Time
Settlement date f	T+2 Irish Business Days
Settlement date f	T+2 Irish Business Days
Domicile	Ireland
Auditors	Grant Thornton
Depository	Northern Trust Fiduciary Services (Ireland) Ltd
Category	UCITS V

Important Information



This document is for the use of Institutional and Professional investors only. Investor rights are available at the website: albemarleasset.com in both Italian and English. The UCITS management company and the AIFM may cease cross-border marketing at any time.

Source: Bloomberg

* Please note the strategy of the fund changed on February 5th, 2020

Sector Breakdown Net Exposure (%)

Top Holdings

NOVARTIS AG-REG	2.97%
SANLORENZO SPA/AMEGLIA	2.89%
SIEMENS HEALTHINEERS AG	2.77%
CONVATEC GROUP PLC	2.75%
TRIGANO SA	2.68%
Total	14.06%

Asset Allocation Exposure (%)

Country Breakdown Net Exposure (%)

Commentary

The Fund posted a positive performance in July, in line with the general European equity market. The main positives had been Getinge, Sonova, Fresenius, Trigano and Siemens Healthineers. Getinge rose as the Swedish company reported solid sales growth and higher margin in Q2 improving the visibility on the full-year guidance and triggering some moderate estimates increase from analysts. Sonova gained as the Swiss company outperformed together with the whole hearing-aid sector as few analysts upgraded the stock on the back of the positive momentum of the hearing-aid market. Trigano rose as the French recreational vehicles producer rebounded from the decline registered in July following the publication of its Q3 sales numbers which undershot analysts estimates. The main detractors to the Fund performance had been Eckert&Ziegler, Astrazeneca, El.En, Accor and Straumann. Eckert&Ziegler declined as Germany's Federal Financial Supervisory Authority launched a special review of its 2024 results concerning the accounting treatment of the Pentixapharm spin-off, moreover one analyst report mentioned increasing competition in its Gallium business and anticipated weak quarterly results coming out in August. El.En underperformed as the laser equipment company experienced a correction after some months of very strong performance. Accor fell amid a weaker performance of the Travel&Leisure segment as US-Iran hostilities restarted in Middle East breaking down the temporary ceasefire previously agreed. During the month the main trades executed had been the sale of Trigano, and the purchase of EssilorLuxottica.

Important Information and Key Risks: please refer to the KIID and prospectus for full risk details

Investing in the Fund involves material risks, including equity market risks, sector concentration, currency and liquidity risks; the capital invested and any income may rise or fall, and investors could lose the full amount invested, and the Fund may lose value. This information is communicated by Albemarle Asset Management Limited, which is authorised and regulated by the Financial Conduct Authority. This material does not constitute a recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. This can only be distributed to persons who are Professional Clients or Eligible Counterparties, not intended for the general public. Returns expressed in EUR may rise or fall for investors whose local currency is different. You may not get back the amount invested. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. Opinions expressed herein reflect the opinion of Albemarle Asset Management Limited and are subject to change without notice. No part of this document may be reproduced in any manner without the written permission of Albemarle Asset Management Limited, however recipients may pass on this document but only to others falling within this category. This information should be read alongside the fund's prospectus (the prospectus and KID are available in English) or supplement documentation before making an investment decision. If you are unsure if any of the products and portfolios featured are the right choice for you, please seek independent financial advice provided by regulated third parties.